Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

40 results about "Sindbis virus" patented technology

Sindbis virus (SINV) is a member of the Togaviridae family, in the alphavirus subfamily. The virus was first isolated in 1952 in Cairo, Egypt. The virus is transmitted by mosquitoes (Culex spp.) SINV causes sindbis fever in humans and the symptoms include arthralgia, rash and malaise. Sindbis fever is most common in South and East Africa, Egypt, Israel, Philippines and parts of Australia. Sindbis virus is an "arbovirus" (arthropod-borne) and is maintained in nature by transmission between vertebrate (bird) hosts and invertebrate (mosquito) vectors. Humans are infected with Sindbis virus when bitten by an infected mosquito. SINV has been linked to Pogosta disease in Finland, Ockelbo disease in Sweden and Karelian fever in Russia.

Lentiviral vectors pseudotyped with a sindbis virus envelope glycoprotein

Lentiviral vector particles comprising a Sindbis virus E2 glycoprotein variant and a lentiviral vector genome comprising a sequence of interest are provided. A lentiviral vector particle comprising: (a) an envelope comprising a Sindbis virus E2 glycoprotein variant; and (b) a lentiviral vector genome comprising a sequence of interest; wherein the E2 glycoprotein variant facilitates infection of dendritic cells by the lentiviral vector particle, and wherein the E2 glycoprotein variant has reduced binding to heparan sulfate compared to a reference sequence (HR strain).
Owner:IMMUNE DESIGN CORP

Novel helper plasmid, defective sindbis viral vectors and methods of use thereof

Disclosed herein are new defective Sindbis viral vectors made from a novel Helper plasmid, with differences in envelope proteins between JT vectors and consensus Sindbis virus sequences, and also between JT and Ar-339 vectors. Also disclosed are vectors produced using the plasmid, methods for producing the vectors, methods for treating mammals suffering from tumors and pharmaceutical formulations for use in the treatment methods.
Owner:NEW YORK UNIV

Method for carrying out virus inactivation on pig fibrinogens through freeze-drying and heating

The invention discloses a method for carrying out virus inactivation on pig fibrinogens through freeze-drying and heating. The method comprises the following steps: carrying out pretreatment on pig plasmas so as to obtain a concentrated pig fibrinogen solution; adding a group protectant into the concentrated solution; adjusting the pH value of the obtained mixture to 7.5-8.5; enabling the obtained mixture to pass a filter with a bore diameter of 0.2mu m; carrying out aseptic filling, freeze-drying and capping seal on the obtained solution by using 2.5mL perfume bottle so as to obtain a freeze-dried pig fibrinogen product; and carrying out heat preservation on the freeze-dried pig fibrinogen product 139-141 hours at a temperature of 63-67 DEG C so as to carry out hot air viral inactivation. The method disclosed by the invention is verified by National Institute for the Control of Pharmaceutical and Biological Products (No.624 [2008] of NICPBP), through adding Sindbis viruses and PPV viruses to carry out verification, the inactivation effect is remarkable. In the method, through using a simple and feasible freeze-drying product virus inactivating method, the requirements for drying and sterilizing aseptic environments are reduced, the risk of animal-based virus infection in pig fiber products is reduced, and the influence (arising from the traditional virus inactivation) on the bioactivities such as proteins and the like of a product is avoided.
Owner:浙江赛灵特医药科技有限公司

Pharmaceutical composition for treatment of cancers

An object of the present invention is to find a new oncolytic virus and to utilize it for treatment of cancers. The present invention relates to a pharmaceutical composition for treatment of cancers containing Sindbis virus as an active ingredient, a method for treatment of cancers, which comprises administering a therapeutically effective amount of Sindbis virus to a mammal having cancers, a method for identifying cancers, which comprises introducing Sindbis virus into an animal, thereby detecting a Sindbis virus protein or Sindbis virus RNA in vital tissues of the above animal, a method of identifying cancers, which comprises introducing into an animal Sindbis virus having a reporter gene incorporated therein, thereby, detecting the product of said reporter gene in vital tissues of said animal, and a method of identifying cancers, which comprises detecting a increase in antibody titer to the Sindbis virus protein or the product of the reporter gene in the aforementioned animals. It is confirmed that Sindbis virus has cytopathic effects upon various cancer cell lines in vitro, and that reduction in tumor size or disappearance of tumor takes place in vivo. Therefore, Sindbis virus is effective for treatment of cancers. In addition, Sindbis virus shows selective proliferation in a tumor, and is effective for identification or diagnosis for cancers within the living body.
Owner:SHINO YUJI +3

Method for carrying out virus inactivation on pig fibrinogens through freeze-drying and heating

The invention discloses a method for carrying out virus inactivation on pig fibrinogens through freeze-drying and heating. The method comprises the following steps: carrying out pretreatment on pig plasmas so as to obtain a concentrated pig fibrinogen solution; adding a group protectant into the concentrated solution; adjusting the pH value of the obtained mixture to 7.5-8.5; enabling the obtained mixture to pass a filter with a bore diameter of 0.2mu m; carrying out aseptic filling, freeze-drying and capping seal on the obtained solution by using 2.5mL perfume bottle so as to obtain a freeze-dried pig fibrinogen product; and carrying out heat preservation on the freeze-dried pig fibrinogen product 139-141 hours at a temperature of 63-67 DEG C so as to carry out hot air viral inactivation. The method disclosed by the invention is verified by National Institute for the Control of Pharmaceutical and Biological Products (No.624 [2008] of NICPBP), through adding Sindbis viruses and PPV viruses to carry out verification, the inactivation effect is remarkable. In the method, through using a simple and feasible freeze-drying product virus inactivating method, the requirements for drying and sterilizing aseptic environments are reduced, the risk of animal-based virus infection in pig fiber products is reduced, and the influence (arising from the traditional virus inactivation) on the bioactivities such as proteins and the like of a product is avoided.
Owner:浙江赛灵特医药科技有限公司

Primer probe group and kit for combined detection of Sindbis virus and Getah virus based on dual fluorescence PCR method

The invention discloses a primer probe group and kit for combined detection of Sindbis virus and Getah virus based on a dual fluorescence PCR method. The primer probe group contains specific primers and probes aiming at the Sindbis virus as well as primers and probes aiming at the Getah virus, wherein the specific primers aiming at the Sindbis virus include a forward primer and a reverse primer, the nucleotide sequence of the forward primer aiming at the Sindbis virus is represented by SEQ ID No.1, and the nucleotide sequence of the reverse primer aiming at the Sindbis virus is represented bySEQ ID No.2; and the specific primers aiming at the Getah virus include a forward primer and a reverse primer, the nucleotide sequence of the forward primer aiming at the Getah virus is represented bySEQ ID No.3, and the nucleotide sequence of the reverse primer aiming at the Getah virus is represented by SEQ ID No.4. The primer probe group and the kit utilizing the primer probe group can be usedfor effectively detecting the Sindbis virus and the Getah virus, and the detection sensitivity can reach 1*10<3>copies/ml, so that the detection blanks of the Sindbis virus and the Getah virus in theprior art are effectively overcome, and the primer probe group and the kit have high industrial utilization values.
Owner:广东省疾病预防控制中心 +1

Method for preparing tetanus human immune globulin by double virus inactivation

The invention discloses a method for preparing tetanus human immune globulin by double virus inactivation. The method comprises separating and purifying blood plasma from healthy people containing high-potency tetanus antibody by a low-temperature ethanol protein-separating method, and inactivating virus at the pH value of 4.0 after incubation at 23-25 DEG C for 21 days and treating with DV50 nanometer anti-virus membrane for double virus inactivation. The method of the invention has the beneficial effects that the tetanus human immune globulin prepared by double virus inactivation can greatly reduce disease transmitted by blood products, and the quality of products fully complies with the requirement of Pharmacopoeia of People's Republic of China. Through a test using the pseudorabies virus, Sindbis virus and human immunodeficiency virus (HIV), the virus titer (TCID50) can be decreased by at least 4.00log. The safety and reliability of the products are ensured. The tetanus human immune globulin is particularly suitable for people allergic to tetanus antitoxin (TAT).
Owner:新疆德源生物工程有限公司

Sindbis virus vector and virus particles thereof, and application of Sindbis virus vector and virus particles thereof in neural circuit

The invention discloses a Sindbis virus vector and virus particles thereof, and application of the Sindbis virus vector and virus particles thereof in a neural circuit. The Sindbis virus particles carrying a green fluorescent protein gene are successfully prepared by transfecting cells with the Sindbis virus vector with a nucleotide sequence of SEQ ID NO. 1. The virus particles can infect a plurality of cells in vitro, can replicate and proliferate after infection, and can carry out forward cross-multistage-synapse propagation in a mouse cranial neural circuit; and the virus particles have a wide application value in the aspects of cranial neural circuit marking and tracing, marking of non-human primate nerve cells, establishment of a drug screening platform, research and development of pharmaceutical virus inhibition action mechanisms, viral vaccines and diagnostic reagents, establishment of animal models, analysis of virus replication and pathogenesis mechanisms and the like.
Owner:中国科学院深圳理工大学筹

Sindbis virus XJ-160 defective replicon and construction method and application thereof

The invention provides a sindbis virus XJ-160 defective replicon and a construction method and application thereof. The construction method comprises the steps of constructing an XJ-160 virus particle type replicon carrier pVa-XJ, constructing XJ-160 particle type replicons pVaXJ-EGFP and pVaXJ-GLUC containing reporter genes, constructing a XJ-160 defective replicon, utilizing Acl I restriction enzyme to respectively perform single digestion of the VaXJ-EGFP and the pVaXJ-GLUC and constructing defective particles pVaXJ-EGFP delta and pVaXJ-GLUC delta with 1139 base deletions at the positions of non-structural genes. The mechanism of the construction method is that due to the partial absence of non-structural genes regions, a large amount of the reporter genes cannot be expressed normally after cells are introduced into the defective replicon, and non-structural protein expressed by virus can remedy and react on expression of the large amount of the reporter genes caused by the defective replicon when alphavirus infection exists in the cells. The sindbis virus XJ-160 defective replicon can detect multiple types of alphavirus, has not reaction on non-alphavirus and is high in specificity and sensitivity and can detect 1PFU virus. Operation is simple and quick, required instruments are few, sustainability is strong, the virus is not required to be killed in detection, and the sindbis virus XJ-160 defective replicon is suitable for quick identification of the alphavirus.
Owner:中国疾病预防控制中心病毒病预防控制所
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products